Newsfeeds - Spark Newswire

3 minute read

UroGen Highlights New Data Presented at AUA On JELMYTO

Today, 10:28 AM

-- Multi-Center Retrospective Study was Presented at the 2022 American Urological Association Annual Meeting in New Orleans -- NEW ORLEANS--(BUSINESS WIRE)-- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company

URGN

12 minute read

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

Today, 10:28 AM

On Monday, 198 companies reached new 52-week lows.

ADV

1 minute read

UroGen Pharma: Q1 Earnings Insights

By Benzinga Insights

Today, 10:28 AM

UroGen Pharma (NASDAQ:URGN) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

URGN

20 minute read

Earnings Scheduled For May 10, 2022

By Benzinga Insights

Today, 10:28 AM

Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.

ABCL

6 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For April 27, 2022

By Benzinga Insights

Today, 10:28 AM

ACC

1 minute read

Berenberg Initiates Coverage On UroGen Pharma with Buy Rating, Announces Price Target of $20

By Benzinga Newsdesk

Today, 10:28 AM

Berenberg initiates coverage on UroGen Pharma (NASDAQ:URGN) with a Buy rating and announces Price Target of $20.

URGN

2 minute read

UroGen Reports FDA Clearance Of Investigational New Drug Application For UGN-301 Intravesical Solution In Recurrent Non-Muscle Invasive Bladder Cancer

By Benzinga Newsdesk

Today, 10:28 AM

--Multi-arm Phase 1 study will evaluate the safety, tolerability and establish the recommended Phase 2 dose of monotherapy and combination therapy to treat recurrent non-muscle invasive bladder cancer (NMIBC) --Study

URGN

1 minute read

UroGen Pharma Q4 EPS $(1.27) Misses $(1.17) Estimate, Sales $16.17M Miss $16.49M Estimate

By Benzinga Newsdesk

Today, 10:28 AM

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(1.27) per share which missed the analyst consensus estimate of $(1.17) by 8.55 percent. This is a 7.97 percent increase over losses of $(1.38) per share from the

URGN

2 minute read

Earnings Scheduled For March 21, 2022

By Benzinga Insights

Today, 10:28 AM

Companies Reporting Before The Bell • Marinus Pharmaceuticals (NASDAQ:MRNS) is likely to report quarterly loss at $0.76 per share on revenue of $3.37 million.

AUGX

1 minute read

Earnings

How To Attend UroGen Pharma Q4 2021 Earnings Conference Call

By Benzinga Insights

Today, 10:28 AM

UroGen Pharma (NASDAQ:URGN) will host a conference call at 10:00 AM ET on March 21, 2022, to discuss Q4 2021 earnings results. How to Attend UroGen Pharma (URGN) Conference Call Follow this link to access the live webcast.

URGN